ZURICH Roche’s Tecentriq immuno-oncology drug failed a late-stage follow-up trial against advanced bladder cancer, the Swiss drugmaker said on Wednesday, raising questions about whether regulators could scale back their approval of the medicine.
Roche, the world’s biggest maker...
https://goo.gl/3aEuzF
Wednesday, 10 May 2017
Roche's star cancer drug stumbles in study, raising doubts about future | Reuters
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment